ES2987582T3 - Biomarcadores relacionados con la progresión de la resistencia a la Insulina y métodos que lo utilizan - Google Patents
Biomarcadores relacionados con la progresión de la resistencia a la Insulina y métodos que lo utilizan Download PDFInfo
- Publication number
- ES2987582T3 ES2987582T3 ES17209399T ES17209399T ES2987582T3 ES 2987582 T3 ES2987582 T3 ES 2987582T3 ES 17209399 T ES17209399 T ES 17209399T ES 17209399 T ES17209399 T ES 17209399T ES 2987582 T3 ES2987582 T3 ES 2987582T3
- Authority
- ES
- Spain
- Prior art keywords
- biomarkers
- diabetes
- subject
- level
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- G16Z99/00—Subject matter not provided for in other main groups of this subclass
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Data Mining & Analysis (AREA)
- Primary Health Care (AREA)
- Databases & Information Systems (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361758924P | 2013-01-31 | 2013-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2987582T3 true ES2987582T3 (es) | 2024-11-15 |
Family
ID=51262841
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17209399T Active ES2987582T3 (es) | 2013-01-31 | 2014-01-16 | Biomarcadores relacionados con la progresión de la resistencia a la Insulina y métodos que lo utilizan |
| ES14746017.4T Active ES2669620T3 (es) | 2013-01-31 | 2014-01-16 | Biomarcadores relacionados con el avance de la resistencia a la insulina y métodos que lo utilizan |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14746017.4T Active ES2669620T3 (es) | 2013-01-31 | 2014-01-16 | Biomarcadores relacionados con el avance de la resistencia a la insulina y métodos que lo utilizan |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9910047B2 (https=) |
| EP (2) | EP3321686B1 (https=) |
| JP (1) | JP6404834B2 (https=) |
| ES (2) | ES2987582T3 (https=) |
| WO (1) | WO2014120449A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2907525A1 (en) * | 2013-03-28 | 2014-10-02 | Nestec S.A. | Indoxyl sulfate as a biomarker of prebiotic efficacy for weight gain prevention |
| US10060932B2 (en) * | 2013-07-09 | 2018-08-28 | Stemina Biomarker Discovery, Inc. | Biomarkers of autism spectrum disorder |
| JP6609282B2 (ja) * | 2016-05-17 | 2019-11-20 | 国立大学法人大阪大学 | 糖尿病を判定するための血液試料の分析方法及びシステム |
| EP3465202B1 (en) | 2016-06-02 | 2023-07-05 | Metabolon, Inc. | Mass spectrometry method for detection and quantitation of metabolites |
| ES3004083T3 (en) * | 2016-12-19 | 2025-03-11 | Metabolon Inc | Mass spectrometry assay method for detection and quantitation of kidney function metabolites |
| WO2018150077A1 (en) * | 2017-02-16 | 2018-08-23 | Afekta Technologies Oy | Betaine biomarkers for nutritional status, nutritional regimen, endogenous metabolism, or risk of cardiovascular or metabolic diseases |
| CN118883748A (zh) * | 2017-03-31 | 2024-11-01 | 奎斯特诊断投资有限公司 | 用于定量胰岛素和c-肽的方法 |
| EP3401683A1 (en) * | 2017-05-10 | 2018-11-14 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Diagnosing metabolic disease by the use of a biomarker |
| CN111727038B (zh) * | 2018-01-17 | 2025-05-13 | 南安普顿大学 | 肌肉减少症和nad缺乏的风险预测及分级方法 |
| EP3857232A1 (en) * | 2018-09-27 | 2021-08-04 | Société des Produits Nestlé S.A. | Markers of risk to develop insulin resistance during childhood and young adulthood |
| US11041847B1 (en) | 2019-01-25 | 2021-06-22 | Ixcela, Inc. | Detection and modification of gut microbial population |
| KR102231928B1 (ko) * | 2019-09-19 | 2021-03-26 | 고려대학교 산학협력단 | 비만대사수술 이후 당뇨병 예후 예측용 바이오마커 조성물 |
| WO2021222309A1 (en) * | 2020-04-27 | 2021-11-04 | Ixcela, Inc. | Detection and modification of gut microbial population |
| CN112149311B (zh) * | 2020-10-12 | 2021-10-26 | 北京中恒利华石油技术研究所 | 一种基于数量规约的非线性多元统计回归测井曲线预测方法 |
| CN112843036A (zh) * | 2021-01-29 | 2021-05-28 | 中国药科大学 | β-羟基丙酮酸在制备人胰岛淀粉样多肽聚集抑制剂中的应用 |
| CN116087487B (zh) * | 2021-11-08 | 2025-06-03 | 中国医学科学院阜外医院 | 糖尿病患者早期预测心血管疾病（cvd）的生物标志物及其用途 |
| CN114324662B (zh) * | 2021-12-30 | 2022-09-16 | 中南大学 | 用于诊断或预防糖尿病的血清生物标志物的应用 |
| EP4504961A1 (en) * | 2022-04-07 | 2025-02-12 | Need4Health B.V. | Method for determining insulin dosage |
| JP7736971B2 (ja) * | 2022-10-18 | 2025-09-10 | 株式会社オルトメディコ | 糖尿病境界域者のスクリーニング方法 |
| WO2024097429A1 (en) * | 2022-11-05 | 2024-05-10 | Texas Tech University System | Methods and tools for assessing cardiometabolic health and hidden disease risk among apparently healthy individuals |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7329489B2 (en) | 2000-04-14 | 2008-02-12 | Matabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| US20020009740A1 (en) | 2000-04-14 | 2002-01-24 | Rima Kaddurah-Daouk | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| WO2005094200A2 (en) | 2003-06-20 | 2005-10-13 | University Of Florida | Biomarkers for differentiating between type 2 and type 2 diabetes |
| US7682782B2 (en) | 2004-10-29 | 2010-03-23 | Affymetrix, Inc. | System, method, and product for multiple wavelength detection using single source excitation |
| US8119358B2 (en) * | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
| EP2339346B1 (en) * | 2006-03-24 | 2014-09-03 | Metanomics GmbH | Methods for predicting diabetes type II |
| MX2010000414A (es) | 2007-07-17 | 2010-04-01 | Metabolon Inc | Biomarcadores para prediabetes, enfermedades cardiovasculares y otros trastornos relacionados con sindrome metabolico, y metodos de uso de los mismos. |
| WO2010005982A2 (en) | 2008-07-07 | 2010-01-14 | The General Hospital Corporation | Multiplexed biomarkers of insulin resistance |
| WO2010007106A1 (en) * | 2008-07-15 | 2010-01-21 | Metanomics Health Gmbh | Means and methods diagnosing gastric bypass and conditions related thereto |
| US20120122981A1 (en) | 2009-03-31 | 2012-05-17 | Yun Fu Hu | Biomarkers Related to Insulin Resistance and Methods using the Same |
| US8367418B2 (en) * | 2009-10-23 | 2013-02-05 | Therasyn Sensors, Inc. | Method and system to provide personalized pharmaceutical compositions and dosages |
| US9217747B2 (en) * | 2009-10-29 | 2015-12-22 | Health Diagnostic Laboratory, Inc. | Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes |
| US20140303228A1 (en) * | 2011-10-18 | 2014-10-09 | Metabolon, Inc. | Biomarkers for Amyotrophic Lateral Sclerosis and Methods Using the Same |
| US20150065366A1 (en) * | 2011-11-11 | 2015-03-05 | Metabolon, Inc. | Biomarkers for Bladder Cancer and Methods Using the Same |
| CA2853202A1 (en) * | 2011-12-09 | 2013-06-13 | Metabolon, Inc. | Biomarkers for kidney cancer and methods using the same |
-
2014
- 2014-01-16 WO PCT/US2014/011759 patent/WO2014120449A1/en not_active Ceased
- 2014-01-16 US US14/763,962 patent/US9910047B2/en active Active
- 2014-01-16 ES ES17209399T patent/ES2987582T3/es active Active
- 2014-01-16 JP JP2015556042A patent/JP6404834B2/ja active Active
- 2014-01-16 EP EP17209399.9A patent/EP3321686B1/en active Active
- 2014-01-16 EP EP14746017.4A patent/EP2951313B1/en active Active
- 2014-01-16 ES ES14746017.4T patent/ES2669620T3/es active Active
-
2018
- 2018-01-16 US US15/872,373 patent/US20180203021A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9910047B2 (en) | 2018-03-06 |
| ES2669620T3 (es) | 2018-05-28 |
| JP2016509222A (ja) | 2016-03-24 |
| EP3321686B1 (en) | 2024-03-13 |
| US20150362510A1 (en) | 2015-12-17 |
| EP2951313B1 (en) | 2018-03-07 |
| EP2951313A4 (en) | 2016-11-02 |
| JP6404834B2 (ja) | 2018-10-17 |
| WO2014120449A1 (en) | 2014-08-07 |
| HK1217516A1 (en) | 2017-01-13 |
| US20180203021A1 (en) | 2018-07-19 |
| EP3321686A1 (en) | 2018-05-16 |
| EP2951313A1 (en) | 2015-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2987582T3 (es) | Biomarcadores relacionados con la progresión de la resistencia a la Insulina y métodos que lo utilizan | |
| Wolak-Dinsmore et al. | A novel NMR-based assay to measure circulating concentrations of branched-chain amino acids: Elevation in subjects with type 2 diabetes mellitus and association with carotid intima media thickness | |
| Tu et al. | Serum 25-hydroxyvitamin D predicts the short-term outcomes of Chinese patients with acute ischaemic stroke | |
| Chonchol et al. | Relationship of uric acid with progression of kidney disease | |
| ES2443540T3 (es) | Biomarcadores para pre-diabetes y métodos que usan los mismos | |
| CN104956228B (zh) | 己酰甘氨酸作为增重和肥胖倾向的生物标志物 | |
| WO2019195638A1 (en) | Systems and methods for measuring obesity using metabolome analysis | |
| Kunutsor et al. | Plasma calprotectin and risk of cardiovascular disease: Findings from the PREVEND prospective cohort study | |
| US10302663B2 (en) | Method of assessing pancreatic beta-cell function | |
| US20120122981A1 (en) | Biomarkers Related to Insulin Resistance and Methods using the Same | |
| Owens et al. | An integrated biochemical prediction model of all-cause mortality in patients undergoing lower extremity bypass surgery for advanced peripheral artery disease | |
| Tuomisto et al. | A plasma metabolite score of three eicosanoids predicts incident type 2 diabetes: a prospective study in three independent cohorts | |
| Ottas | The metabolomic profiling of psoriasis, atopic dermatitis and atherosclerosis | |
| CN118866120B (zh) | 预测脓毒症患者死亡高风险的生物标志物、系统及其应用 | |
| La Sala et al. | One-hour plasma glucose combined with skin autofluorescence identifies subjects with pre-diabetes: the DIAPASON study | |
| Murphy et al. | Clinical outcomes following burn injury across the continuum of chronic glycemic control | |
| Ackermans et al. | Serum metabolomics analysis for quantification of muscle loss in critically ill patients: an explorative study | |
| CN118806773B (zh) | Udca系列胆汁酸在预防脓毒症肠道炎症损伤中的作用机制及其应用 | |
| Busto et al. | A six-year risk assessment for dementia and Alzheimer's disease in the general population through immunoprecipitation-mass spectrometry plasma amyloid quantification | |
| Petersson | Exploring metabolic and functional changes in stroke patients: insights from a urinary and blood-derived metabolomic study | |
| Saini et al. | Urinary biomarkers in metabolic syndromes | |
| Qiao et al. | U-shaped relationship between weight-adjusted waist index and acute exacerbation of chronic obstructive pulmonary disease in critically ill patients | |
| HK1217516B (en) | Biomarkers related to insulin resistance progression and methods using the same | |
| Tian et al. | Two user-friendly models and a simple cutoff value of neutrophil to lymphocyte ratio (NLR) for early diagnosis of diabetic nephropathy in middle-elderly aged patients with type 2 diabetes: A cross-sectional study | |
| Żórawik et al. | Cardiovascular risk assessed using the SCORE system and blood renalase concentration in the Polish subpopulation of the PURE study |